1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC).
Saved in:
| Title: | 1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). |
|---|---|
| Authors: | Eminowicz, G.1 (AUTHOR), Alexandre, J.2 (AUTHOR), Sanchez, L.M. Manso3 (AUTHOR), Braicu, I.4 (AUTHOR), Madry, R.5 (AUTHOR), Taskiran, C.6 (AUTHOR), Farolfi, A.7 (AUTHOR), Vulsteke, C.8 (AUTHOR), Hasegawa, K.9 (AUTHOR), Wang, J.10 (AUTHOR), Kim, J-W.11 (AUTHOR), Ananda, S.12 (AUTHOR), Tan, D.S.13 (AUTHOR), Crafton, S.14 (AUTHOR), Black, D.15 (AUTHOR), Slomovitz, B.M.16 (AUTHOR), Orlowski, R.J.17 (AUTHOR), Kruger, S.F.17 (AUTHOR), Yao, L.18 (AUTHOR), Monk, B.J.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS790-S790. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 189419660 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Eminowicz%2C+G%2E%22">Eminowicz, G.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Alexandre%2C+J%2E%22">Alexandre, J.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sanchez%2C+L%2EM%2E+Manso%22">Sanchez, L.M. Manso</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Braicu%2C+I%2E%22">Braicu, I.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Madry%2C+R%2E%22">Madry, R.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Taskiran%2C+C%2E%22">Taskiran, C.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Farolfi%2C+A%2E%22">Farolfi, A.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vulsteke%2C+C%2E%22">Vulsteke, C.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hasegawa%2C+K%2E%22">Hasegawa, K.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+J%2E%22">Wang, J.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+J-W%2E%22">Kim, J-W.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ananda%2C+S%2E%22">Ananda, S.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tan%2C+D%2ES%2E%22">Tan, D.S.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Crafton%2C+S%2E%22">Crafton, S.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Black%2C+D%2E%22">Black, D.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Slomovitz%2C+B%2EM%2E%22">Slomovitz, B.M.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Orlowski%2C+R%2EJ%2E%22">Orlowski, R.J.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kruger%2C+S%2EF%2E%22">Kruger, S.F.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yao%2C+L%2E%22">Yao, L.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Monk%2C+B%2EJ%2E%22">Monk, B.J.</searchLink><relatesTo>19</relatesTo> (AUTHOR) – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS790-S790. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189419660 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.annonc.2025.08.1856 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S790 Titles: – TitleFull: 1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Eminowicz, G. – PersonEntity: Name: NameFull: Alexandre, J. – PersonEntity: Name: NameFull: Sanchez, L.M. Manso – PersonEntity: Name: NameFull: Braicu, I. – PersonEntity: Name: NameFull: Madry, R. – PersonEntity: Name: NameFull: Taskiran, C. – PersonEntity: Name: NameFull: Farolfi, A. – PersonEntity: Name: NameFull: Vulsteke, C. – PersonEntity: Name: NameFull: Hasegawa, K. – PersonEntity: Name: NameFull: Wang, J. – PersonEntity: Name: NameFull: Kim, J-W. – PersonEntity: Name: NameFull: Ananda, S. – PersonEntity: Name: NameFull: Tan, D.S. – PersonEntity: Name: NameFull: Crafton, S. – PersonEntity: Name: NameFull: Black, D. – PersonEntity: Name: NameFull: Slomovitz, B.M. – PersonEntity: Name: NameFull: Orlowski, R.J. – PersonEntity: Name: NameFull: Kruger, S.F. – PersonEntity: Name: NameFull: Yao, L. – PersonEntity: Name: NameFull: Monk, B.J. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 09 Text: 2025 Supplement 2 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 09237534 Numbering: – Type: volume Value: 36 Titles: – TitleFull: Annals of Oncology Type: main |
| ResultId | 1 |
